Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Jabbour, E
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. [electronic resource] - Leukemia Feb 2011 - 201-10 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2010.215 doi
Benzamides
Dasatinib
Disease Management
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--complications
Piperazines--adverse effects
Protein Kinase Inhibitors--adverse effects
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrimidines--adverse effects
Thiazoles--adverse effects
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. [electronic resource] - Leukemia Feb 2011 - 201-10 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2010.215 doi
Benzamides
Dasatinib
Disease Management
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--complications
Piperazines--adverse effects
Protein Kinase Inhibitors--adverse effects
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrimidines--adverse effects
Thiazoles--adverse effects